Cancer is one of the first areas where precision medicine was applied in a clinical setting. Today, particularly in developed countries such as the U.S. and U.K., it is becoming increasingly common to undergo precision diagnostic testing and subsequent targeted therapy depending on the tumor mutations and type of cancer.…

Sponsored content brought to you by Identifying tumor biomarkers and characterizing their function in cancer cells help provide valuable data to guide the development and selection of personalized therapies and treatment plans for patients that may improve health outcomes and survivorship. The pace of innovation in precision medicine testing technologies…

Oncology-focused real-world evidence (RWE) company ConcertAI and molecular science and technology company Caris Life Sciences announced they will develop a clinico-genomic data platform that combines comprehensive molecular profiling data with reference-standard clinical data to enable precision oncology research. The partnership expands on an agreement reached by the companies in January…

Although incremental innovations in technology and our understanding of cancer biology have led us into a Golden Age, it is only in the last couple of decades, with the emergence and convergence of several technologies, that we can fully reap the rewards of those innovations. And this wealth of understanding…

Sponsored content brought to you by Life-extending targeted treatment options are emerging at an accelerated pace, but cancer cases across the world still continue to rise. And unfortunately, the number of clinical oncologists available to treat these cancer patients is declining. As a result, cancer continues to significantly impact the…

Personalized therapy simulation company Cellworks announced on Monday the launch of two separate business units that will take an in silico approach to testing potential new precision oncology drugs in both pre-clinical and clinical stages. The services, the company said, will both accelerate the development of promising therapies in a…

Sponsored content brought to you by Strata Oncology CEO and co-founder Dan Rhodes, PhD, describes how molecular testing of tumors as it exists today is insufficient to realize the full promise of precision cancer care, and how Strata has developed a new category of tests that provides comprehensive treatment selection…

Today the field of digital pathology can trace its roots to the end of the last century with the development of the “virtual microscope” by a combined team of researchers at the University of Maryland’s department of computer science and researchers in the department of pathology at Johns Hopkins University…

Regional integrated health network Avera Health, with more than 300 locations in the Upper Midwest, and AI-enabled genomic and clinical data intelligence company Sema4 announced today the formal launch of a five-year population health study focused on improving precision oncology care. Dubbed the Avera/Sema4 Oncology and Analytics Protocol (ASAP) study,…

Sponsored content brought to you by Inside Precision Medicine (IPM) sat down with Brady Davis, Chief Business Officer at Canexia Health, to get a snapshot of the strategic goals behind the recent merger and understand what this means for the company’s future growth and how this strengthened commercial capability will…

When Anne Donguy’s son, Anatole, was diagnosed with diffuse midline glioma in May 2018, she joined the ranks of many parents around the world looking for any effective treatment for their child. Living in Stockholm, Sweden, Anne and her family eventually learned that the most hopeful drug treatment, Onc201, was…

Personal Genome Diagnostics Inc. (PGDx) is being acquired by testing giant Labcorp for $450M. PGDx offers the elio tissue complete diagnostic kit, which is cleared by the U.S. Food and Drug Administration (FDA) for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.  Because it is a kit, and incorporates…

Cancer-focused molecular testing and technology company Caris Life Sciences announced today that the National Cancer Institute’s (NCI) Center for Cancer Research (CCR) has joined the Caris Precision Oncology Alliance (POA) to collaborate on precision medicine research. Under the collaboration, Caris will make available to NCI researchers its broad portfolio of…

Sioux Falls, SD-based Avera Health, which runs 35 hospitals, 215 primary and specialty care clinics, 40 senior living facilities in South Dakota, North Dakota, Iowa, Nebraska, and Minnesota, have announced a collaboration with health intelligence company Sema4 with an initial focus on advancing Avera’s precision oncology program. Managed through the…

Proteome-focused precision medicine drug developer Frontier Medicines announced today it closed an $88.5 million Series B financing round. The financing was co-led by Woodline Partners LP and RA Capital Management, with equal participation by Deerfield Management Company. Proceeds will be used in the development of the company’s foundational technologies of…